Skip to main content
. 2022 Sep 7;41:267. doi: 10.1186/s13046-022-02482-3

Fig. 6.

Fig. 6

DOX/sh-1@PLT inhibits HCC development and DOX resistance in vivo. A Schematic illustration of the treatment regimen. B-C Fluorescence intensity alterations (B) and representative images (C) in HCC model mice were detected. D Detection of fluorescence changes of intensity in livers of HCC-bearing mice. E Detection of tumor weight. F Detection of the number of tumor lesions. *P < 0.05, **P < 0.01